InsiderTrades.com logo

QNCX Insider Trading

Insider Ownership Percentage: 7.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Quince Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Quince Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Quince Therapeutics Share Price & Price History

Current Price: $16.36
Price Change: ▼ Price Decrease of -1.83 (-10.06%)
As of 07/1/2026 12:23 PM ET

This chart shows the closing price history over time for QNCX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Quince Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/29/2024Dirk ThyeCEOBuy387$138.00$53,406.003,834View SEC Filing Icon  
8/21/2024Brendan HannahCOOBuy154$126.00$19,404.001,482View SEC Filing Icon  
8/20/2024Charles S. RyanPresidentBuy241$130.00$31,330.00612View SEC Filing Icon  
8/19/2024Brendan HannahCOOBuy10$116.00$1,160.001,298View SEC Filing Icon  
12/14/2023David LamondDirectorBuy113$208.00$23,504.0011,737View SEC Filing Icon  
12/12/2023David LamondDirectorBuy111$204.00$22,644.0011,511View SEC Filing Icon  
12/7/2023David LamondDirectorBuy95$202.00$19,190.0011,398View SEC Filing Icon  
12/5/2023David LamondDirectorBuy95$202.00$19,190.0011,207View SEC Filing Icon  
12/1/2023David LamondDirectorBuy71$188.00$13,348.0011,111View SEC Filing Icon  
11/29/2023David LamondDirectorBuy71$196.00$13,916.0010,967View SEC Filing Icon  
8/30/2023David LamondDirectorBuy205$262.00$53,710.0010,690View SEC Filing Icon  
8/17/2023David LamondDirectorBuy123$258.00$31,734.0010,485View SEC Filing Icon  
8/15/2023David LamondDirectorBuy539$264.00$142,296.009,774View SEC Filing Icon  
8/10/2023Dirk ThyeCEOBuy440$252.00$110,880.002,244View SEC Filing Icon  
8/8/2023Brendan HannahInsiderBuy358$244.00$87,352.001,007View SEC Filing Icon  
8/8/2023Dirk ThyeCEOBuy400$248.00$99,200.001,804View SEC Filing Icon  
8/8/2023Margaret McloughlinDirectorBuy40$246.00$9,840.0040View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Quince Therapeutics (NASDAQ:QNCX)

30.75% of Quince Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at QNCX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Quince Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/18/2026Superstring Capital Management LP858,711$2.88M1.5%N/A1.542%Search for SEC Filing on Google Icon
2/18/2026Quadrature Capital Ltd80,134$0.27M0.0%N/A0.144%Search for SEC Filing on Google Icon
2/18/2026Millennium Management LLC1,190,352$3.99M0.0%-14.2%2.138%Search for SEC Filing on Google Icon
2/18/2026683 Capital Management LLC238,177$0.80M0.0%N/A0.428%Search for SEC Filing on Google Icon
2/17/2026Almitas Capital LLC930,134$3.12M0.7%+88.0%1.670%Search for SEC Filing on Google Icon
2/17/2026Adage Capital Partners GP L.L.C.2,250,000$7.54M0.0%N/A4.041%Search for SEC Filing on Google Icon
2/16/2026OMERS ADMINISTRATION Corp92,000$0.31M0.0%N/A0.165%Search for SEC Filing on Google Icon
2/13/2026Nantahala Capital Management LLC2,672,429$8.95M0.3%-13.1%4.800%Search for SEC Filing on Google Icon
2/13/2026Marshall Wace LLP511,858$1.72M0.0%+143.7%0.919%Search for SEC Filing on Google Icon
2/13/2026Hudson Bay Capital Management LP63,471$0.21M0.0%N/A0.114%Search for SEC Filing on Google Icon
2/12/2026Jane Street Group LLC521,072$1.75M0.0%+1,382.0%0.936%Search for SEC Filing on Google Icon
2/12/2026Renaissance Technologies LLC538,100$1.80M0.0%+14.8%0.966%Search for SEC Filing on Google Icon
2/11/2026Cerity Partners LLC189,789$0.64M0.0%N/A0.341%Search for SEC Filing on Google Icon
2/10/2026Intellectus Partners LLC53,312$0.18M0.0%N/A0.096%Search for SEC Filing on Google Icon
2/10/2026Goldman Sachs Group Inc.229,695$0.77M0.0%N/A0.413%Search for SEC Filing on Google Icon
2/9/2026Geode Capital Management LLC523,899$1.76M0.0%+19.8%0.941%Search for SEC Filing on Google Icon
11/17/2025Nantahala Capital Management LLC3,073,729$5.01M0.2%+21.6%5.520%Search for SEC Filing on Google Icon
11/17/2025Millennium Management LLC1,386,776$2.26M0.0%+1,152.9%2.491%Search for SEC Filing on Google Icon
11/17/2025Almitas Capital LLC494,778$0.81M0.2%N/A0.889%Search for SEC Filing on Google Icon
11/14/2025ADAR1 Capital Management LLC775,034$1.26M0.1%+442.1%1.443%Search for SEC Filing on Google Icon
11/14/2025Shay Capital LLC136,955$0.22M0.0%-8.7%0.255%Search for SEC Filing on Google Icon
11/14/2025Bridgeway Capital Management LLC95,122$0.16M0.0%-26.0%0.177%Search for SEC Filing on Google Icon
11/14/2025Union Square Park Capital Management LLC224,746$0.37M0.1%+86.0%0.418%Search for SEC Filing on Google Icon
11/7/2025GSA Capital Partners LLP87,235$0.14M0.0%+158.0%0.162%Search for SEC Filing on Google Icon
11/7/2025Vanguard Group Inc.1,763,387$2.87M0.0%+21.3%3.283%Search for SEC Filing on Google Icon
8/15/2025Shay Capital LLC150,000$0.25M0.0%-18.6%0.279%Search for SEC Filing on Google Icon
8/15/2025Bridgeway Capital Management LLC128,617$0.21M0.0%+20.9%0.239%Search for SEC Filing on Google Icon
8/14/2025Nantahala Capital Management LLC2,528,302$4.17M0.2%N/A4.707%Search for SEC Filing on Google Icon
8/12/2025XTX Topco Ltd22,660$37K0.0%N/A0.042%Search for SEC Filing on Google Icon
8/8/2025Rockefeller Capital Management L.P.169,554$0.28M0.0%N/A0.316%Search for SEC Filing on Google Icon
5/14/2025Ieq Capital LLC806,780$1.07M0.0%N/A1.828%Search for SEC Filing on Google Icon
5/12/2025Virtu Financial LLC43,332$58K0.0%+48.4%0.098%Search for SEC Filing on Google Icon
4/11/2025Intellectus Partners LLC53,312$71K0.0%N/A0.121%Search for SEC Filing on Google Icon
2/17/2025Two Sigma Investments LP30,341$57K0.0%N/A0.069%Search for SEC Filing on Google Icon
2/17/2025Shay Capital LLC276,799$0.52M0.1%+60.8%0.629%Search for SEC Filing on Google Icon
2/14/2025Northern Trust Corp50,524$94K0.0%+48.5%0.115%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC375,932$0.70M0.0%+10.9%0.854%Search for SEC Filing on Google Icon
2/11/2025Virtu Financial LLC29,204$55K0.0%N/A0.066%Search for SEC Filing on Google Icon
2/5/2025Anfield Capital Management LLC26,656$50K0.0%N/A0.061%Search for SEC Filing on Google Icon
1/24/2025Scharf Investments LLC91,061$0.17M0.0%N/A0.207%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC339,125$0.26M0.0%+24.2%0.784%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC483,902$0.36M0.0%-7.0%1.120%Search for SEC Filing on Google Icon
1/12/2024Scharf Investments LLC91,061$96K0.0%N/A0.212%Search for SEC Filing on Google Icon
7/31/2023Intellectus Partners LLC53,527$81K0.0%N/A0.148%Search for SEC Filing on Google Icon
7/24/2023BML Capital Management LLC1,411,839$2.13M1.9%N/A3.892%Search for SEC Filing on Google Icon
5/11/2023EPIQ Capital Group LLC958,469$1.50M0.8%-9.3%2.642%Search for SEC Filing on Google Icon
4/20/2023Hennion & Walsh Asset Management Inc.31,061$48K0.0%N/A0.086%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Quince Therapeutics logo
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
Read More on Quince Therapeutics

Today's Range

Now: $16.36
Low: $16.30
High: $18.03

50 Day Range

MA: $22.08
Low: $18.01
High: $27.40

52 Week Range

Now: $16.36
Low: $15.80
High: $909.98

Volume

35,261 shs

Average Volume

286,624 shs

Market Capitalization

$320.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Who are the company insiders with the largest holdings of Quince Therapeutics?

Quince Therapeutics' top insider shareholders include:
  1. David Lamond (Director)
  2. Dirk Thye (CEO)
  3. Brendan Hannah (COO)
  4. Brendan Hannah (Insider)
  5. Charles S Ryan (President)
  6. Ted Monohon (CAO)
  7. Margaret Mcloughlin (Director)
Learn More about top insider investors at Quince Therapeutics.

Quince Therapeutics Active Insiders

Dirk Thye
Dirk Thye
Chief Executive Officer, Chief Medical Officer, and Board Member
Charles S Ryan
Charles S Ryan
President
Brendan Hannah
Brendan Hannah
Chief Operating Officer & Chief Business Officer